

22nd September, 2019

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Closure of USFDA inspection at API manufacturing facility in Virgonagar

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that following the inspection by the United States Food and Drug Administration (USFDA) at Company's API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.

Kindly take the above information on record.

Thanking you,

Yours faithfully
For Cipla Limited



Rajendra Chopra
Company Secretary & Compliance Officer

Prepared by Gaurav Sainani